These Analysts Revise Their Forecasts On BioNTech After Q2 Results
I'm PortAI, I can summarize articles.
BioNTech SE reported a narrower Q2 loss of $1.82 per share, beating the consensus loss of $2.42. Sales reached $295.69 million, surpassing expectations. The company reaffirmed its 2025 revenue guidance of 1.7-2.2 billion euros. Analysts revised their price targets: B of A raised it from $126 to $134, while Wells Fargo lowered it from $170 to $150. BioNTech shares rose 0.9% to $111.05 following the earnings announcement.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Benzinga The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments